Expression of Progesterone Receptor A as an Independent Negative Prognosticator for Cervical Cancer

The role of progesterone receptor A (PRA) for the survival outcome of cervical cancer patients is ambiguous. In mouse models, it has been shown that PRA plays a rather protective role in cancer development. The aim of this study was to assess its expression by immunohistochemistry in 250 cervical cancer tissue samples and to correlate the results with clinicopathological parameters including patient survival. PRA expression was positively correlated with the International Federation of Gynecology and Obstetrics (FIGO) classification scores. PRA was significantly overexpressed in adenocarcinomas compared to squamous epithelial carcinoma subtypes. Correlation analyses revealed a trend association with the HPV virus protein E6, a negative correlation with p16 and a positive correlation with EP3. PRA expression was also associated with the expression of RIP140, a transcriptional coregulator that we previously identified as a negative prognostic factor for survival in cervical cancer patients. Univariate survival analyses revealed PRA as a negative prognosticator for survival in patients with cervical adenocarcinoma. Multivariate analyses showed that simultaneous expression of RIP140 and PRA was associated with the worst survival, whereas with negative RIP140, PRA expression alone was associated with the best survival. We can therefore assume that the effect of nuclear PRA on overall survival is dependent upon nuclear RIP140 expression.

[1]  L. Banks,et al.  Regulation of HPV E7 Stability by E6-Associated Protein (E6AP) , 2022, Journal of virology.

[2]  G. Ingravallo,et al.  Association between Cervical Microbiota and HPV: Could This Be the Key to Complete Cervical Cancer Eradication? , 2022, Biology.

[3]  Kongming Wu,et al.  Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study , 2021, Biomarker research.

[4]  Chin-Yo Lin,et al.  Progesterone Receptor Is a Haploinsufficient Tumor-Suppressor Gene in Cervical Cancer , 2020, Molecular Cancer Research.

[5]  Kaiyu Liu,et al.  p16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1A axis , 2020, Journal of Cancer.

[6]  B. Niesler,et al.  Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology , 2019, Cancer management and research.

[7]  U. Jeschke,et al.  Glucocorticoid receptor in cervical cancer: an immunhistochemical analysis , 2018, Archives of Gynecology and Obstetrics.

[8]  Xia Li,et al.  Downregulation of RIP140 in triple-negative breast cancer inhibits the growth and proliferation of cancer cells. , 2018, Oncology letters.

[9]  U. Jeschke,et al.  Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer , 2017, Oncotarget.

[10]  Henry W. Long,et al.  Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling , 2017, Oncotarget.

[11]  S. de Sanjosé,et al.  The natural history of human papillomavirus infection. , 2017, Best practice & research. Clinical obstetrics & gynaecology.

[12]  C. Alexiou,et al.  The involvement of E6, p53, p16, MDM2 and Gal-3 in the clinical outcome of patients with cervical cancer , 2017, Oncology letters.

[13]  U. Jeschke,et al.  The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients , 2017, International journal of molecular sciences.

[14]  Y. Hsu,et al.  Expression of Estrogen and Progesterone Receptor in Tumor Stroma Predicts Favorable Prognosis of Cervical Squamous Cell Carcinoma , 2017, International Journal of Gynecologic Cancer.

[15]  Xueqiong Zhu,et al.  Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis , 2017, Oncotarget.

[16]  U. Jeschke,et al.  Histone H3 Acetyl K9 and Histone H3 Tri Methyl K4 as Prognostic Markers for Patients with Cervical Cancer , 2017, International journal of molecular sciences.

[17]  C. Alexiou,et al.  Immunohistochemical Evaluation of the Role of p53 Mutation in Cervical Cancer: Ser-20 p53-Mutant Correlates with Better Prognosis. , 2016, Anticancer research.

[18]  M. Newton,et al.  Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling , 2015, Proceedings of the National Academy of Sciences.

[19]  Caroline H. Diep,et al.  Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells , 2013, Cell cycle.

[20]  Matti Poutanen,et al.  The transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signals , 2013, Development.

[21]  M. lenhard,et al.  Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival , 2012, BMC Cancer.

[22]  M. lenhard,et al.  Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients , 2012, BMC Research Notes.

[23]  B. Katzenellenbogen,et al.  Aryl hydrocarbon receptor modulation of estrogen receptor α-mediated gene regulation by a multimeric chromatin complex involving the two receptors and the coregulator RIP140. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[24]  D. Greaves,et al.  NF-κB-mediated degradation of the co-activator RIP140 regulates inflammatory response and contributes to endotoxin tolerance , 2012, Nature Immunology.

[25]  Marius C. Jones,et al.  Role of nuclear receptor corepressor RIP140 in metabolic syndrome☆ , 2011, Biochimica et biophysica acta.

[26]  S. Hilsenbeck,et al.  Progesterone Receptor Isoform-Specific Promoter Methylation: Association of PRA Promoter Methylation with Worse Outcome in Breast Cancer Patients , 2011, Clinical Cancer Research.

[27]  S. Wacholder,et al.  Human papillomavirus testing in the prevention of cervical cancer. , 2011, Journal of the National Cancer Institute.

[28]  U. Jeschke,et al.  Immunohistochemical expression of glycodelin in breast cancer correlates with estrogen-receptor alpha and progesterone-receptor A positivity. , 2009, Histology and histopathology.

[29]  H. Sommer,et al.  Prognostic significance of oestrogen receptor alpha (ERα) and beta (ERβ), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas , 2007 .

[30]  I. Jacobs,et al.  Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. , 2007, Oncology reports.

[31]  Susan G. Hilsenbeck,et al.  Breast Cancer Patients with Progesterone Receptor PR-A-Rich Tumors Have Poorer Disease-Free Survival Rates , 2004, Clinical Cancer Research.

[32]  H. Bernard,et al.  The human papillomavirus type 11 and 16 E6 proteins modulate the cell-cycle regulator and transcription cofactor TRIP-Br1. , 2003, Virology.

[33]  J. Gustafsson,et al.  Regulation of Subnuclear Localization Is Associated with a Mechanism for Nuclear Receptor Corepression by RIP140 , 2003, Molecular and Cellular Biology.

[34]  P. Clement,et al.  Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis , 2002, Histopathology.

[35]  T. Mak,et al.  ERK Activation Mediates Cell Cycle Arrest and Apoptosis after DNA Damage Independently of p53* , 2002, The Journal of Biological Chemistry.

[36]  R. Cardiff,et al.  Impact of progesterone receptor on cell-fate decisions during mammary gland development. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Sidransky,et al.  Role of the p16 tumor suppressor gene in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Kushner,et al.  Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. , 1995, The EMBO journal.

[39]  F. Marmé,et al.  The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer , 2017, Journal of Cancer Research and Clinical Oncology.